Active	Status	Sponsor type	Region	Phase	Filter
14 Active 9 Inactive 23 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lee, Fa-Chyi
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer	Active, not recruiting	2/3	700	US	GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin	Gritstone bio, Inc.	Colorectal Neoplasms	03/27	03/27
ASIST, NCT05322590: BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma	Active, not recruiting	1/2	195	US	BXQ-350, SapC-DOPS, Placebo	Bexion Pharmaceuticals, Inc., ICON plc, CTI Clinical Trial and Consulting Services	Metastatic Colorectal Carcinoma, Neuropathy	04/26	04/29
Cho, May T
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer	Active, not recruiting	2/3	700	US	GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin	Gritstone bio, Inc.	Colorectal Neoplasms	03/27	03/27
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease	Recruiting	2/3	1912	Canada, US	Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month	NRG Oncology, Natera, Inc., National Cancer Institute (NCI)	Stage III Colon Cancer	03/29	03/30
NCT05733611: RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	Active, not recruiting	2	4	NA	RP2, RP3, atezolizumab, bevacizumab	Replimune Inc., Roche Pharma AG	Refractory Metastatic Colorectal Cancer, pMMR, MSS	01/27	03/27
NCT03516708: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer Jan 2019 - Jan 2019 : P1/2 trial in advanced rectal cancer	Recruiting	1/2	49	US	Epacadostat, INCB024360, Short-course radiation therapy, SCRT, CAPOX chemotherapy, FOLFOX chemotherapy	Washington University School of Medicine, Incyte Corporation, National Cancer Institute (NCI)	Rectal Cancer	07/27	08/30
ARTACUS, NCT04349436: A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies	Recruiting	1/2	65	US	RP1, intra-tumoral injection, oncolytic virus	Replimune Inc.	Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Melanoma	09/27	01/28
Aguilar, Luisa Mejia
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer	Active, not recruiting	2/3	700	US	GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin	Gritstone bio, Inc.	Colorectal Neoplasms	03/27	03/27